Background: Preeclapmsia (PE) is characterized by early onset symptoms such as elevated blood
pressure, proteinuria and edema in the pregnant woman, and may result in seizures in the affected
woman. Currently, there are no therapeutic drugs available to treat this condition, but there are
interventions to regulate the symptoms based on the gestational period of the fetus, although the
largely favored option is the delivery of the fetus and placenta.
Objective: A search for biomolecules associated with PE so as to identify diagnostic markers and
Results: The literature search resulted in the identification of biomolecules such as corin and placental
protein 13 (PP13), among others that are associated with PE. Thereby, giving an insight into the various
mechanistic pathways involved in the causation of PE. However, it is also evident that PE cannot be
solely attributed to any single mechanism but is due an interplay of different factors that has led to the
development of this disease condition.
Conclusion: The identified biomarkers would ultimately help in understanding this complex disease and
perhaps lead to the discovery of potential effective molecular targets for clinical trials, thereby providing
a valuable therapeutic option for affected pregnant women.